CCCC (c4therapeutics.com) Enterprise Value-to-Revenue Coefficient

Official company branding of C4 Therapeutics Inc (CCCC)

C4 Therapeutics, Inc. (CCCC) develops innovative oncology drugs leveraging a proprietary protein degradation system for long-term sustainability. The EV/Sales multiple helps assess the business value relative to revenue, with 5274.47 representing the current value of this metric. Successes with the drug CFT7455 and partnerships with industry behemoths are driving share growth. High confidence among scientists confirms the fundamental strength of the company's scientific foundation.

c4therapeutics.com (CCCC): EV/Sales Multiple from 11/23/2025 to 11/20/2026

Financial and market metric breakdowns for C4 Therapeutics (CCCC)

- price and consensus price forecast:
- business market valuation indicators:
Fundamental company valuation:C4 Therapeutics, Inc. CCCC
Product sample of c4therapeutics.com

C4 Therapeutics, Inc. (CCCC) maintains minimal internal capex due to the outsourcing of production and testing to third-party contractors. The EV/Sales metric relates the total enterprise value, including debt, to sales volume, thereby eliminating the impact of financial leverage. This allows for an assessment of the market value of every dollar of revenue without distortions from the capital structure. Investors decouple fundamental value from volatility by analyzing changes in EV/Sales. The trend of this indicator reveals asset overvaluation relative to actual operational scale.